Cormorant Asset Management

Founded 2013


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 134
Average round size
The average size of a deal this fund participated in
Portfolio companies 125
Rounds per year 16.75
Lead investments 15
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 70
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical

The main department of described VC is located in the Boston. The fund was located in North America if to be more exact in United States.

Among the most popular fund investment industries, there are Medical, Life Science. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Innovent Biologics, ZAI Lab

The increased amount of exits for fund were in 2018. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars. When the investment is from Cormorant Asset Management the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. This Cormorant Asset Management works on 22 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 13-24 investment rounds annually.

We also calculated 2 valuable employees in our database.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Cormorant Asset Management, startups are often financed by ARCH Venture Partners, Third Rock Ventures, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Wellington Management, EcoR1 Capital. In the next rounds fund is usually obtained by EcoR1 Capital, Visionnaire Ventures, Senvest Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Cormorant Asset Management:
Typical Co-investors
Cormorant Asset Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Cormorant Asset Management:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Vigil Neuroscience

$90M18 Aug 2021 United States, Cambridge

Prime Medicine

$200M13 Jul 2021 United States, Cambridge

Tioga Medical

Health Care
Medical Device
$30M07 Jul 2021 United States, " United States"}

Umoja Biopharma

Developer Platform
Information Technology
$210M15 Jun 2021 United States, Seattle

Health Care
Medical Device
$17M01 Jun 2021 United States, " United States"}

Health Care
28 May 2021 China, Yinzhou District

NiKang Therapeutics

Health Care
$200M26 May 2021 United States, Wilmington


Life Science
Medical Device
$19M20 May 2021 United States, Houston


Health Diagnostics
Life Science
$109M19 May 2021 Switzerland, " Switzerland"}
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Cormorant Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: